is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever

NCT07130305 | Recruiting

• 1 other identifier: IRB00014233-33
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Familial mediterranean fever (FMF) is common in mediterranean region. this disorder is connected with deterioration in functional performance, fitness of cardiorespiration, muscle strength, and bone mass

Conditions

Familial Mediterranean Fever

Outcome Measures

Primary Outcomes (1)

• bone mineral density

  it is a measure for bone density at 2-4 lumbar vertebrae

  it will be measured after 6 months

Secondary Outcomes (7)

• z score

  it will be measured after 6 months

• vitamin D

  it will be measured after 6 months

• osteoprotegerin

  it will be measured after 6 months

• quadriceps torque

  it will be measured after 6 months

• Standing long jump test

  it will be measured after 6 months

Study Arms (2)

vibration group

EXPERIMENTAL

vibration group OF FMF will contain 20 FMF adolescent girls. who will receive vitamin D and their traditional colchicine doses daily for six months. vibration group will receive also three sessions of 20-min whole body vibration in the week for 6 months

Other: whole body vibration plus usual care

control group

ACTIVE COMPARATOR

control group of Familial mediterranean fever (20 FMF adolescent girls ) will receive vitamin D and their traditional colchicine doses daily for six months.

Other: usual care

Interventions

whole body vibration plus usual care OTHER

Familial mediterranean fever (20 FMF adolescent girls ) will be in this vibration group who will receive vitamin D and their traditional colchicine doses daily for six months. vibration group will also receive three sessions of 20-min whole body vibration in the week for 6 months

vibration group

usual care OTHER

Familial mediterranean fever (20 FMF adolescent girls ) will be in this control group who will receive vitamin D and their traditional colchicine doses daily for six months.

control group

Eligibility Criteria

• Age: 13 Years - 17 Years
• Gender Eligibility Details: based on self-representation of gender identity.
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• FMF adolecent girls ages 13 -17 years forty patients

You may not qualify if:

• cardiac problems renal problems liver problems diabetes brain problems

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Cairo University

Giza, Dokki, Egypt

RECRUITING

MeSH Terms

Conditions

Familial Mediterranean Fever

Condition Hierarchy (Ancestors)

Hereditary Autoinflammatory Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Ali MA Ismail, lecturer

  Cairo University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ali MA Ismail, lecturer

CONTACT

01005154209; ali.mohamed@pt.cu.edu.eg

Ali Ismail

CONTACT

allooka2012@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: lecturer of physical therapy for Cardiovascular, Respiratory disorder and Geriatrics, Faculty of Physical Therapy, Cairo University

Study Record Dates

• First Submitted: August 12, 2025
• First Posted: August 19, 2025
• Study Start: May 8, 2025
• Primary Completion: January 8, 2026
• Study Completion: January 15, 2026
• Last Updated: August 19, 2025

Record last verified: 2025-08

Locations

EG (1)